KANSAS CITY, Mo., Jan. 9, 2025 /PRNewswire/ — Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco January 13-16.
Details of the event:
During the event, members of Vivacelle’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
About Vivacelle Bio
Vivacelle Bio is a late-stage biopharma company developing life-saving treatments for shock and trauma. The company’s lead, Phase 3 product, VBI-S, is built on its pioneering and patented phospholipid nanoparticle technology, which leverages the redistribution of nitric oxide to treat multisystem organ failure and elevate blood pressure in hypovolemic septic shock, a leading cause of death that impacts millions around the world. A Phase 2 trial of VBI-S demonstrated 100% efficacy, with the treatment resulting in elevated blood …